Approvals for 505(b)(2) Drugs Slower Than for NMEs, Report Says

The 505(b)(2) approval pathway, designed to expedite reviews, actually takes about five months longer than the standard NDA process, says a new report from the Tufts Center for the Study of Drug Development.
Source: Drug Industry Daily